BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$301.92 USD
+5.10 (1.72%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $302.11 +0.19 (0.06%) 4:44 PM ET
3-Hold of 5 3
C Value C Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BIO 301.92 +5.10(1.72%)
Will BIO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIO
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
Is It Wise to Hold Bio-Rad (BIO) Stock in Your Portfolio Now?
BIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Phibro (PAHC) Down 3.3% Since Last Earnings Report: Can It Rebound?
Why Is Bio-Rad (BIO) Up 7.8% Since Last Earnings Report?
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down
Other News for BIO
Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024
Bullish Two Hundred Day Moving Average Cross - BIO
Ariel Investments Q1 2024 Small Cap Value Strategy Letter
Ariel Investments Mid Cap Value Q1 2024 Commentary
RBC Capital Remains a Buy on Bio-Rad Laboratories (BIO)